Tag Archives: mental health

Healthcare

Algae Dynamics Corp Announces Research Agreement With University of Western Ontario to Investigate the Use of Cannabis Derivatives for the Development of Novel Pharmacotherapies for Mental Health

Leave a comment

Algae Dynamics announces a development agreement with Western University to do research on cannabis oil in the context of depression, post-traumatic stress disorder & schizophrenia.

Toronto, Canada — ALGAE DYNAMICS CORP (OTCQB: ADYNF) (the “Company”), a development stage company focused on the development of unique health products and pharmaceuticals utilizing cannabis and algae oils, today announced a research and product development agreement with Western University to perform research on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia. This is the second of the recently announced research agreements with Canadian universities involving cannabis oil research. This announcement brings Algae Dynamics total university research contributions to $1.6 million for both programs.

This announcement follows the Company’s previously announced new strategic initiative to explore the extraction of oils from other botanicals, most notably cannabis, and to seek product development and formulation opportunities that combine the benefits of algae and cannabis oils. This research agreement will directly support this initiative and will “focus on translational pharmaceutical research, with a specific focus on identifying how specific phytochemical compounds found in cannabis, including delta-9-tetrahydrocannbinol (THC), cannabidiol (CBD), cannabinoid-derived terpenoids and other potential phytochemical derivatives of cannabis may serve as novel pharmacological treatments for symptoms associated with depression, post-traumatic stress disorder, anxiety and schizophrenia.”

Paul Ramsay, Chairman and President of the Company said, “With this research agreement, we are building upon the previously announced strategic initiative into the use of extracts from cannabis oil, in conjunction with algae oil, to develop unique health products and formulations. In our previous press release, we outlined a three-part approach, the first being Research and Development work with Canadian universities. This is the second of such research agreements relating to the use of botanical extracts including cannabinoids that we expect to employ”.

The investigator leading the research is Dr. Steven Laviolette, a Professor and Neuroscientist in the Schulich School of Medicine & Dentistry at Western University. Dr. Laviolette is a leader in the study of cannabinoids in mental health. Dr. Laviolette’s research team has previously made numerous fundamental discoveries related to how cannabinoids impact and may serve as treatments for mental health disorders including schizophrenia, depression, post-traumatic stress disorder and anxiety. Dr. Laviolette’s primary research focus is in characterizing how specific phytochemical derivatives of cannabis may interact with specific brain pathways and molecular mechanisms whereby they may improve symptoms associated with various mental health disorders. Research from Dr. Laviolette’s team has been published in the top neuroscience and psychiatry journals in the world. His full profile may be seen on the Western University, website http://www.uwo.ca:

http://www.schulich.uwo.ca/anatomy/people/bios/faculty/laviolette_steve.html

The Company’s contribution to the four-year Sponsored Research Agreement, which commences April 1, 2017 and terminates March 30, 2021, is C$250,000 per year. The Company believes, from past experience, that it will be able to leverage the research expenditures with matching scientific grants pursuant to programs of various branches of government. The Company will be responsible for the filing of patents relating to this research and will own such patents if and when issued. The Company has agreed to make payments to the University upon filing of each patent, when each patent is issued, after first commercial sale and when gross sales reach C$1,000,000. There are no ongoing royalty payments, relating to the use of the patents. The workplan may be extended and modified to achieve best outcomes which may include 1) delegating specific research areas of research work that require additional technologies to appropriate providers; and 2) engaging research collaborators to extend the research into additional areas of benefit to the Company.

The Company’s core product development strategy has been the production of high volume specific algae species and extraction of Essential Fatty Acids (EFAs) which is the foundation of the endocannabinoid system (ECS). The ECS is a group of endogenous cannabinoid receptors located in the mammalian brain and throughout the central and peripheral nervous systems, consisting of neuromodulatory lipids and their receptors. The extracted algae Omega 3 oil with high concentrations of DHA is used as a health supplement product. In light of the potential synergies, the Company has developed its strategy which is aimed at developing new products and formulations that combine the health benefits of algae and cannabis oils.

As reported earlier, the Company is continuing to seek opportunities to partner with or take ownership in existing Access to Cannabis for Medical Purposes Regulations (ACMPR) licensed producers to allow for access to the marketplace.

About Algae Dynamics Corp
ADC is currently engaged in the development of unique health products and pharmaceuticals that utilize hemp, cannabis and algae oils. This is an extension of our plan to commercialize our proprietary BioSilo® algae cultivation system for the high volume, low cost production of pure contaminant-free algae biomass which is high in Omega-3 fatty acids. We have engaged two Canadian universities to provide research into the use of extracts from cannabis oil, which we plan to use to develop products that combine the significant health benefits of Omega-3s derived from algae oil and extracts from cannabis oil. Our research is focusing on the use of cannabis oil in the context of cancer, and the use of cannabis derivatives for the development of novel pharmacotherapies for mental health.

NOTE REGARDING FORWARD-LOOKING STATEMENTS
This news release contains “forward-looking statements” as that term is defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, use of proceeds and the development, costs and results of current or future actions and opportunities in the sector. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, our ability to raise the additional funding we will need to continue to pursue our exploration and development program, and our ability to retain important members of our management team and attract other qualified personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

FOR MORE INFORMATION, PLEASE CONTACT:
Paul Ramsay
Phone: 289-997-6740
Email: ramsay(at)algaedynamics.com
http://www.algaedynamics.com

Healthcare

Prison Coach Welcomes Dr. C Tyrone Jennings as Director of Mental Health Services

Leave a comment

Dr. Jennings has extensive experience as a Forensic Counselor in the Criminal Justice system. it provided a direct relationship with government agencies in the Criminal Justice and Mental/Behavioral Health industries, i.e. F.B.I., U.S .Marshall’s Office, Parole Commission, U.S. Attorney’s Office, Bureau of Prisons and the Federal Judiciary.

New York, NY (USA), February 25, 2013 — Prison Coach has reinvented the prison consulting industry again by welcoming Dr. C Tyrone Jennings to the Prison Coach team ( http://www.prisoncoach.com ). President Steve Oberfest states “Dr. Jennings role as Director of Mental Health is extremely vital in that prior to self-surrendering and upon reentry into society our client’s mental health is extremely important. Prison Coach is the most respected and first company to begin prison consulting and it’s important that we continue setting the standard for all prison consultants who are popping up throughout the country.”

Dr. Jennings explained his role and objective as the Prison Coach Director of Mental Health Services “Through the Prison Coach mental health component, it will allow me to introduce to the offender, how to survive emotionally, psychologically, mentally and therapeutically , utilizing concepts of Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), Behavioral Modification, De-Escalation Strategies, Systematic Desensitization (SD), and Rational-Emotive Behavioral Therapy. These are but a minuscule approach to the development, re-shaping and modification of one’s cognition and application of pro-social values and socially acceptable thought automation.”

Vice President John Fuller stated “Prison Consulting is about ensuring that Vietnam Veterans, substance abusers, white collar professionals and others who have led criminal lifestyles receive proper pre and post incarceration treatmentp; particularly if there is a history of drug and alcohol abuse. Dr. Tyrone Jennings is the best person on the planet to provide such.” Fuller further stated “Too many Prison Consultant companies have surfaced since we began and make false promises to reduce sentences by filing 2255 Motions for ineffective assistance of counsel against their attorneys. They should focus on the client’s mental and emotional well-being and leave the legal work to attorneys who are equipped to handle those matters.” Oberfest stated “By the time that motion is filed and responded by the Circuit Court a client could have committed suicide due to a condition linked to criminality such as antisocial personality disorder, impulse contr ol disorders which are linked to criminal behaviors where as effective preparation might have prepared them to cope with prison if their case were denied. This position is right up Dr. Jennings alley.”

As prison consultants, Oberfest and Fuller spend a majority of their time public speaking at high schools, colleges and corporation. Volunteering their time to speak with troubled youth in inner cities is equally important to them. Dr. Jennings will play a pivotal role in that area also.

Oberfest, Fuller and Jennings are expected to speak with “At Risk Youths” on February 27, 2013 at the Belmont Academy located at 631 Belmont Ave, Brooklyn, NY 11207.

For more information about “Prison Coach and Dr. C Tyrone Jennings PhD”, visit their website http://www.prisoncoach.com

Press & Media Contact:
John Fuller
Prison Coach LLC
330 E 75th St
New York, NY, 10023 – USA
732-406-2834
prisoncoach247@gmail.com
http://www.prisoncoach.com

Healthcare, Science, Technology

Scientific Breakthroughs in Mental Health Diagnoses | Northam Psychotechnologies

Leave a comment

Ottawa, Ontario – The National Mental Health Association reports that over 65 million Americans suffer from some type of mental illness. By 2020, mental illness is projected to be the leading cause of the disease burden in North America. That obviously is a problem of staggering magnitude, with total costs to society in the hundreds of billions every year. Northam Psychotechnologies, an Ottawa, Ontario-based company holds the North American patent pending to futuristic technologies that provide a profoundly powerful solution to this problem.

Semantic Stimuli Response Measurement (SSRM) is a powerful psychological screening tool. It is the world’s first technology designed and utilized to meticulously measure the response of the subconscious mind outside of a laboratory setting. Internationally renowned brain researcher, Dr. Semyon Ioffe, has adapted this technology, which is the direct result of a worldwide body of scientific knowledge, to accommodate the North American conglomerate. He states, “We are the first testing and teaching Technology Company in the areas of Mental Health, and are able to effectively test for and detect early stages of mental disorders. We also test the effectiveness of medical or psychological treatment for mental disorders, and teach patients, on a subconscious level, to free themselves from drug and alcohol addictions, phobias, suicidal tendencies, PTSD and so much more.”

SSRM Tek can effectively enhance treatment accuracy and efficacy by determining the root causes of mental afflictions. Treatment times are significantly reduced. The necessity of follow-up procedures is diminished greatly. Unnecessary treatment methods are eliminated. And the results generated are virtually error-free. “SSRM Tek easily obtains invaluable information from a source that never lies: the subconscious mind.” Dr. Ioffe states further, “This technology has been in development for over five decades. It has surfaced strongly now and is the future of mental health care standards.”

SSRM Tek can determine the effectiveness of the treatment being provided to patients. Concurrent testing and re-testing can determine if the treatment is having positive effects on the patient and is able to follow up on the progress of the treatment. As the world’s first technology to measure the response of the subconscious mind outside a laboratory setting, this precise psychological screening tool can be used broadly in a multitude of fashions. Dr. Ioffe concludes, “We want everyone to feel very confident in requesting more information about SSRM Tek and encourage them to do so freely.”

About Northam Psychotechnologies: Ottawa-based Northam Psychotechnologies is an integrated solutions provider that utilizes SSRM Tek as the key tool to provide solutions for mental health issues. It is a registered Canadian company with shareholders. Northam Psychotechnologies, which holds both the US and Canadian patents pending, is owned by Dr. Semyon Ioffe. Dr. Ioffe, an internationally renowned brain researcher, is widely published and esteemed. A strong band of experts complement the SSRM Tek team, which is fully committed to helping keep North Americans safe and healthy.

Northam Psychotechnologies | Detection | Identification | Treatment

Follow Dr. Ioffe’s on Twitter!